Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240681 | 0.95 | SCD (0.91) | SCD | |
| SCHEMBL12134195 | 0.93 | SCD (0.87) | SCD | |
| SCHEMBL241790 | 0.93 | SCD (1.00) | SCD | |
| SCHEMBL244749 | 0.92 | SCD (0.88) | SCD | |
| SCHEMBL1912057 | 0.92 | SCD (0.88) | SCD | |
| SCHEMBL241507 | 0.92 | SCD (0.91) | SCD | |
| SCHEMBL348527 | 0.91 | SCD (0.83) | SCD | |
| SCHEMBL241834 | 0.91 | SCD (0.83) | SCD | |
| SCHEMBL244273 | 0.90 | SCD (1.00) | SCD | |
| SCHEMBL244372 | 0.90 | SCD (1.00) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| CN-117338941-A | Pharmaceutical composition containing TKIs inhibitor and SCD1 inhibitor and anti-tumor application thereof | 复旦大学附属肿瘤医院 | 2024-01-05 | — | — | CN | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | claimed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | claimed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | claimed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | claimed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| CN-117338941-A | Pharmaceutical composition containing TKIs inhibitor and SCD1 inhibitor and anti-tumor application thereof | 复旦大学附属肿瘤医院 | 2024-01-05 | — | — | CN | disclosed |
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | SCD 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.